A study from the Abramson Family Cancer Research Institute, Philadelphia, USA; and Howard Hughes Medical Institute, Philadelphia, USA shows that “Fructose-1,6-bisphosphatase opposes renal carcinoma progression.”
This study was published in the September issue of 2014 Nature by Prof. M. Celeste Simon, Li B0 [I.F >42] and others from the Abramson Family Cancer Research Institute and Howard Hughes Medical Institute, Philadelphia, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for Renal Cell Carcinoma: Tumor suppressor ING1b increases the expression of Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene. This study may suggest that ING1b, by up regulating its target gene, it may induce FBP1. Thereby, it may inhibit (1) the expression of hypoxia-inducible factor (HIF-1); (2) glycolysis; and (3) the progression of renal cell carcinoma. Together, this study suggests that pharmacological formulations encompassing “ING1b or its activators“ can be used in the treatment of renal cell carcinoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Molecular therapy for Renal Cell Carcinoma: Tumor suppressor ING1b increases the expression of Fructose-1,6-bisphosphatase (FBP1) via up regulation of its target gene, 04/October/2014, 22.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
